(ABM UN) It is still a lackluster session on the Brussels stock exchange on Friday, with the Bel20 rising 0.1 percent to 4,252.00 points.
In the star index, Melexis and UCB both rose by approximately 1.3 percent.
Argenx gave up some ground. The company received approval from Japan’s Ministry of Health, Labor and Welfare, or MHLW, for VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy, or CIDP, the company announced Friday morning.
The MHLW approval is based on the ADHERE trial, the largest clinical trial to date studying CIDP. KBC Securities responded to the news on Friday morning and maintained the price target of 615 euros and the Accumulate advice.
D’Ieteren, on the other hand, lost 1.8 percent.
Bpost managed to make a 2.8 percent gain in territory. The number of Bpost parcel locker installations in Belgium has increased to more than 1,260, an increase of 40 percent.
And Bpost will deliver another 1,200 parcel locker installations in 2025. This doubles the existing network.
Barco, on the other hand, lost 2.2 percent.
The Hyloris share price recorded a gain of more than 16 percent. Hyloris Pharmaceuticals has signed an agreement with Avenacy to exclusively market Tranexamic Acid RTU in the US. Hyloris reported this on Thursday morning.
Hyloris did not provide exact financial details of the deal, only that the profits will be shared between the two companies. It concerns a prepared drug with tranexamic acid, which can be used in hemophiliacs if they need to have a tooth extracted.
An application for approval for this generic treatment has already been submitted to the American regulator FDA. Hyloris expects approval in 2025, after which Avenacy will actually market the drug.
Sequana Medical was again unstoppable and rose by almost 50 percent. The stock market value has increased fivefold in less than a week thanks to the green light from the American FDA for Sequana’s alfapump. That approval also came faster than expected.
Door: ABM Financial News.
[email protected]
Editorial: +32(0)78 486 481
Bron: ABM Financial News
ABM Financial News is the supplier of stock market news in the Benelux. The information in this article is not intended as professional investment advice or as a recommendation to make certain investments.
Community trend
Will the stock rise or fall following this news item?
Community trend
You must be logged in to perform this action. Log in or Sign up
